US 7,563,784 B2
	Protease inhibitors
Maxwell D. Cummings, Strafford, Pa. (US); Robert W. Marquis, Jr., Wayne, Pa. (US); Yu Ru, Wayne, Pa. (US); Scott K. Thompson, Phoenixville, Pa. (US); Daniel F. Veber, Ambler, Pa. (US); and Dennis S. Yamashita, Wayne, Pa. (US)
Assigned to SmithKline Beecham Corporation, King of Prussia, Pa. (US)
Filed on Apr. 25, 2006, as Appl. No. 11/410,558.
Application 11/410558 is a continuation of application No. 10/239343, granted, now 7,071,184, previously published as PCT/US01/07094, filed on Mar. 07, 2001.
Claims priority of provisional application 60/191000, filed on Mar. 21, 2000.
Claims priority of provisional application 60/206341, filed on May 23, 2000.
Claims priority of provisional application 60/211759, filed on Jun. 14, 2000.
Claims priority of provisional application 60/217445, filed on Jul. 10, 2000.
Prior Publication US 2006/0194787 A1, Aug. 31, 2006
Int. Cl. A61P 19/08 (2006.01); A61P 19/10 (2006.01); A61K 31/55 (2006.01); C07D 401/00 (2006.01); C07D 403/00 (2006.01); C07D 413/00 (2006.01)

U.S. Cl. 514—211.03  [514/217.03; 514/217.04; 514/217.05; 514/217.06; 514/217.07; 514/217.08; 514/217.09; 514/217.1; 514/217.11; 540/525; 540/596; 540/597; 540/598; 540/599; 540/601; 540/602; 540/603; 540/604; 540/605]

7 Claims

1. A compound which is 3-methyl-furo[3,2-b]pyridine-2-carboxylic acid {(S)-3-methyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; or a pharmaceutically acceptable salt thereof.